Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma - PubMed (original) (raw)
doi: 10.1002/hep.27944. Epub 2015 Aug 7.
Michael B Campion 2, Minetta C Liu 2 3, Roongruedee Chaiteerakij 1 4, Nasra H Giama 1, Hager Ahmed Mohammed 1, Xiaodan Zhang 1, Chunling Hu 1, Victoria L Campion 1, Jin Jen 2, Sudhakar K Venkatesh 5, Kevin C Halling 2, Benjamin R Kipp 2, Lewis R Roberts 1
Affiliations
- PMID: 26096702
- PMCID: PMC4684812
- DOI: 10.1002/hep.27944
Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma
Ju Dong Yang et al. Hepatology. 2016 Jan.
Abstract
Circulating tumor cells (CTCs) in blood are associated with poor survival of patients with breast, prostate, or colon cancer. We hypothesized that CTCs are associated with poor survival of patients with cholangiocarcinoma (CCA). Eighty-eight patients with CCA were prospectively enrolled at Mayo Clinic Rochester between June 2010 and September 2014. The CellSearch system by Veridex was used for detection of CTCs in peripheral blood. Associations between CTC, patient and tumor characteristics, and survival were examined using the Cox's proportional hazards model. Fifteen patients (17%) were positive for CTC ≥2 and 8 patients (9%) for CTC ≥5. CTCs were associated with tumor extent. CTC ≥2 (hazard ratio [HR]: 2.5; 95% confidence interval [CI]: 1.1-5.4; P = 0.02) and CTC ≥5 (HR, 4.1; 95% CI: 1.4-10.8; P = 0.01) were both independent predictors of survival. In subgroup analyses, CTC ≥2 (HR, 8.2; 95% CI: 1.8-57.5; P < 0.01) and CTC ≥5 (HR, 7.7; 95% CI: 1.4-42.9; P = 0.02) were both associated with shorter survival among patients with metastasis. There was a trend toward association of CTC ≥5 with shorter survival in patients with nonmetastatic CCA (HR, 4.3; 95% CI: 1.0-13.8; P = 0.06). CTC ≥2 (HR, 10.5; 95% CI: 2.2-40.1; P < 0.01) and CTC ≥5 (HR, 10.2; 95% CI: 1.5-42.3; P = 0.02) were both associated with shorter survival among patients with perihilar/distal CCA. CTC ≥5 was associated with shorter survival of patients with intrahepatic CCA (HR, 4.2; 95% CI: 1.1-14.1; P = 0.04).
Conclusion: CTCs were associated with more-aggressive tumor characteristics and independently associated with survival in patients with CCA. Assessment of CTCs may be useful for identifying CCA patients at risk of early mortality.
© 2015 by the American Association for the Study of Liver Diseases.
Conflict of interest statement
Conflict of Interest:
Nothing to disclose except that Minetta C. Liu receives research funding from Veridex/Janssen; all funds are provided to the institution with no personal compensation.
Figures
Figure 1
Kaplan-Meier overall survival estimates according to CTC in patients with CCA A: CTC ≥2 vs. CTC <2 B: CTC ≥5 vs. CTC <5
Figure 2
Kaplan-Meier overall survival estimates according to CTC in patients with metastatic/non-metastatic CCA A: CTC ≥2 vs. CTC <2, Metastatic CCA B: CTC ≥5 vs. CTC <5, Metastatic CCA C: CTC ≥2 vs. CTC <2, Non-metastatic CCA D: CTC ≥5 vs. CTC <5, Non-metastatic CCA
Figure 3
Kaplan-Meier overall survival estimates according to CTC in patients with AJCC/UICC TNM stage of 1–2/3–4 CCA A: CTC ≥2 vs. CTC <2, TNM stage of 3–4 CCA B: CTC ≥5 vs. CTC <5, TNM stage of 3–4 CCA C: CTC ≥2 vs. CTC <2, TNM stage of 1–2 CCA D: CTC ≥5 vs. CTC <5, TNM stage of 1–2 CCA
Figure 4
Kaplan-Meier overall survival estimates according to CTC in patients with intrahepatic/perihilar-distal CCA A: CTC ≥2 vs. CTC <2, Intrahepatic CCA B: CTC ≥5 vs. CTC <5, Intrahepatic CCA C: CTC ≥2 vs. CTC <2, Perihilar-distal CCA D: CTC ≥5 vs. CTC <5, Perihilar-distal CCA
Comment in
- Circulating tumor cells and cholangiocarcinoma.
Giovannoni R, Villanueva A. Giovannoni R, et al. Hepatology. 2016 Jan;63(1):23-5. doi: 10.1002/hep.28152. Epub 2015 Oct 23. Hepatology. 2016. PMID: 26358526 No abstract available.
Similar articles
- Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M. Mu Z, et al. Breast Cancer Res Treat. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4. Epub 2015 Nov 16. Breast Cancer Res Treat. 2015. PMID: 26573830 - Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification.
Tawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, Kelly M, Thinkhamrop B. Tawarungruang C, et al. BMC Cancer. 2021 May 3;21(1):497. doi: 10.1186/s12885-021-08247-z. BMC Cancer. 2021. PMID: 33941120 Free PMC article. - Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma.
Cheng Q, Feng F, Zhu L, Zheng Y, Luo X, Liu C, Yi B, Jiang X. Cheng Q, et al. Sci Rep. 2015 Nov 4;5:16103. doi: 10.1038/srep16103. Sci Rep. 2015. PMID: 26534789 Free PMC article. - The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis.
Lu YJ, Wang P, Wang X, Peng J, Zhu YW, Shen N. Lu YJ, et al. Oncotarget. 2016 Jun 14;7(24):37361-37369. doi: 10.18632/oncotarget.8156. Oncotarget. 2016. PMID: 27008698 Free PMC article. Review.
Cited by
- Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S, Catalano G, Roman D, Zecchetto C, Lucin E, De Bellis M, Tripepi M, Guglielmi A, Milella M, Ruzzenente A. Conci S, et al. Int J Med Sci. 2023 May 11;20(7):858-869. doi: 10.7150/ijms.82008. eCollection 2023. Int J Med Sci. 2023. PMID: 37324191 Free PMC article. Review. - Adjuvant therapy of biliary tract cancers.
Kefas J, Bridgewater J, Vogel A, Stein A, Primrose J. Kefas J, et al. Ther Adv Med Oncol. 2023 Mar 28;15:17588359231163785. doi: 10.1177/17588359231163785. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37007632 Free PMC article. Review. - The Prognostic Significance of Circulating Tumor Cells in Patients with Pancreatobiliary Cancer.
Ünek İT, Öztop İ, Başbınar Y, Ünek T, Leblebici A, Karaca C, Çakıroğlu E, Uysal T, Aysal A, Ellidokuz H, Sağol Ö, Astarcıoğlu İ. Ünek İT, et al. Turk J Gastroenterol. 2023 Mar;34(3):278-286. doi: 10.5152/tjg.2023.22260. Turk J Gastroenterol. 2023. PMID: 36919832 Free PMC article. - Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring.
Choi WJ, Ivanics T, Gravely A, Gallinger S, Sapisochin G, O'Kane GM. Choi WJ, et al. Ann Surg Oncol. 2023 Jun;30(6):3849-3863. doi: 10.1245/s10434-023-13126-x. Epub 2023 Feb 20. Ann Surg Oncol. 2023. PMID: 36808320 Review. - Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma.
Fründt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse AW, Wege H, Schulze K. Fründt T, et al. Front Oncol. 2022 Nov 10;12:941660. doi: 10.3389/fonc.2022.941660. eCollection 2022. Front Oncol. 2022. PMID: 36439492 Free PMC article.
References
- Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods. 2010;50:289–97. - PubMed
- Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10:6897–904. - PubMed
- Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. The Lancet Oncology. 2012;13:688–95. - PubMed
Publication types
MeSH terms
Grants and funding
- R21 CA128633/CA/NCI NIH HHS/United States
- CA100882/CA/NCI NIH HHS/United States
- T32 DK007198/DK/NIDDK NIH HHS/United States
- R01 CA100882/CA/NCI NIH HHS/United States
- R01 CA165076/CA/NCI NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- CA165076/CA/NCI NIH HHS/United States
- CA128633/CA/NCI NIH HHS/United States
- T32 DK07198/DK/NIDDK NIH HHS/United States
- R56 CA100882/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical